James B. Couch, M.D., J.D., director-in-charge of disease management for Coopers & Lybrand Integrated Healthcare Consulting, has published his second book, "The Physician's Guide to Disease Management." However, the comprehensive guide to disease management's initiatives, strategies and trends is not intended only for physicians. Representatives may read it to strengthen their understanding of this popular trend in managed health care.
James B. Couch, M.D., J.D., director-in-charge of disease management for Coopers & Lybrand Integrated Healthcare Consulting, has published his second book, "The Physician's Guide to Disease Management." However, the comprehensive guide to disease management's initiatives, strategies and trends is not intended only for physicians. Representatives may read it to strengthen their understanding of this popular trend in managed health care.
Pharmaceutical Representative: Why is a guide to disease management needed today?
Couch: There are so many misconceptions about what disease or health management is. Every group that has tried to define disease management in one way or another has had a different spin on it. Consequently, we need a book that can tie all the different perspectives together. We need to establish a common framework for what disease management is, as well as what it isn't.
Pharmaceutical Representative: Which diseases are the targets of the different programs?
Couch: Diabetes is one of the diseases and the book discusses how those patients were managed. Prenatal care, asthma and hypertension are also covered.
Pharmaceutical Representative: How can a pharmaceutical representative use your book?
Couch: The entire book is useful for salespeople who are in the business of calling on physicians to help them prescribe the best medicines.
One chapter specifically covers disease management in pharmaceutical companies. Others focus on evidence-based medicine, outcomes-validated clinical practice guidelines and examples of successfully implemented disease management programs.
These chapters would be relevant and interesting to a pharmaceutical representative. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.